About this Research Topic
This Research Topic is part of a series with:
Toxicity Mechanism and Clinical features of PD-1/PD-L1 Inhibitors in Treatment of Cancer, Volume II
PD-1 and PD-L1 inhibitors are important targets in immunotherapy for cancer treatment. Anti-PD-1/PD-L1 antibodies have been developed to combat many cancers as a result of their success compared to conventional cancer treatment with monoclonal antibodies. There has been a total paradigm shift in the treatment of oncological malignancies as more anti-PD-1/PD-L1 agents have also been approved by the FDA (US) and the European Medicines Agency (EMA).
The increase in anti-PD-1/PD-L1 agents use has provoked the emergence of a new spectrum of toxicities. These toxicities depend on the individual patient and the specific type of anti-PD-1/PD-L1 agent used in the treatment. The incidence of fatal cancer immunotherapy associated toxicities is estimated to be between 0.3% and 1.3%. Numerous clinical trials and studies have investigated the treatment-related toxicities of PD-1 and PD-L1 inhibitors. However, further research is required to fully understand the mechanism of these toxicities.
Monoclonal antibodies have been used to address this challenge as they can act as antagonists in the PD-1/PD-L1 signalling pathway but there are still several inherent limitations with this. Thus, there is the need for small molecular inhibitors with the ability to directly block PD-1/PD-L1 or inhibit the translation of PD-L1 by promoting the degradation of PD-L1. Furthermore, the druggability of these small molecule inhibitors must be carefully assessed. This is very important for the success of PD-1/PD-L1 based cancer immunotherapy.
The aim of this Research Topic is to explore the mechanism of pharmacological toxicity induced by PD-1/ PD-L1 inhibitors and explore the difference in the incidence of toxicities between patients treated with PD-1 or PD-L1 inhibitors and those treated without. We welcome submission including but not limited to:
• Original Research on the mechanism of pharmacological toxicity induced by PD-1/ PD-L1 inhibitors in all tissues as well as those in the event of treatment leading to discontinuation.
• Original Research investigating the clinical features of PD-1/ PD-L1 inhibitors’ toxicities
•Studies on single drug toxicities and treatment with PD-1/PD-L1 inhibitors combined with chemotherapy in clinical practice.
• Systematic review and meta-analysis of toxicities of PD-1/ PD-L1 inhibitors in treatment of cancer including single toxicity or multiple toxicities in different systems.
Toxicity Mechanism and Clinical features of PD-1/PD-L1 Inhibitors in Treatment of Cancer, Volume II
PD-1 and PD-L1 inhibitors are important targets in immunotherapy for cancer treatment. Anti-PD-1/PD-L1 antibodies have been developed to combat many cancers as a result of their success compared to conventional cancer treatment with monoclonal antibodies. There has been a total paradigm shift in the treatment of oncological malignancies as more anti-PD-1/PD-L1 agents have also been approved by the FDA (US) and the European Medicines Agency (EMA).
The increase in anti-PD-1/PD-L1 agents use has provoked the emergence of a new spectrum of toxicities. These toxicities depend on the individual patient and the specific type of anti-PD-1/PD-L1 agent used in the treatment. The incidence of fatal cancer immunotherapy associated toxicities is estimated to be between 0.3% and 1.3%. Numerous clinical trials and studies have investigated the treatment-related toxicities of PD-1 and PD-L1 inhibitors. However, further research is required to fully understand the mechanism of these toxicities.
Monoclonal antibodies have been used to address this challenge as they can act as antagonists in the PD-1/PD-L1 signalling pathway but there are still several inherent limitations with this. Thus, there is the need for small molecular inhibitors with the ability to directly block PD-1/PD-L1 or inhibit the translation of PD-L1 by promoting the degradation of PD-L1. Furthermore, the druggability of these small molecule inhibitors must be carefully assessed. This is very important for the success of PD-1/PD-L1 based cancer immunotherapy.
The aim of this Research Topic is to explore the mechanism of pharmacological toxicity induced by PD-1/ PD-L1 inhibitors and explore the difference in the incidence of toxicities between patients treated with PD-1 or PD-L1 inhibitors and those treated without. We welcome submission including but not limited to:
• Original Research on the mechanism of pharmacological toxicity induced by PD-1/ PD-L1 inhibitors in all tissues as well as those in the event of treatment leading to discontinuation.
• Original Research investigating the clinical features of PD-1/ PD-L1 inhibitors’ toxicities
•Studies on single drug toxicities and treatment with PD-1/PD-L1 inhibitors combined with chemotherapy in clinical practice.
• Systematic review and meta-analysis of toxicities of PD-1/ PD-L1 inhibitors in treatment of cancer including single toxicity or multiple toxicities in different systems.
Keywords: immune-checkpoint inhibitors, PD-1/PD-L1 inhibitors, toxicity, clinical features, cancer
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
